Suite 10, Woodmill Lane, Knysna, 6571

Contact Time Mon - Fri: 08h00 - 17h00
Contact Email

Suite 10, Woodmill Lane, Knysna, 6571

Cord blood therapies have shown highly promising results to treat diseases for which there are currently no available therapies. Results using autologous (own) cells in babies and children with HIE, cerebral palsy and autism spectrum disorder are safe and results are promising. The safety of partially or fully matched sibling cord blood infusions has also been demonstrated preliminary.

The Cryo-Save difference – providing families who believe in the future of regenerative medicine and tissue engineering access to current and future stem cell therapies.

Specialised cord blood processing through the Sepax II FAMCORD protocol using a BioSafe Sepax blood processing kit. The kit is a closed, single-use system which minimizes the risk of contamination during processing. UNIQUE IN SA.

Testing cord tissue stem cells to determine viability by fluorescent staining. FIRST IN SA. When storing with Cryo-Save, you are assured that your samples have been properly tested and verified to be suitable for long term storage.

Peace of mind, with photographic evidence of viable tissue stem cells (if required for future expansion and therapy). FIRST IN SA.

Cryo-Save South Africa is owned by two publicly listed companies, providing unmatched financial security for your investment.

Cryo-Save was established in 2000 and is represented in over 30 countries on three continents and is the largest cord blood bank in Europe with 3 laboratories in Geneva, South Africa and UAE. It is ranked the world’s 5th most influential cord blood bank by BioInformant.

Esperite, Cryo-Save’s holding company in Europe, registered a patent to use cord tissue stem cells that will enable new, and more accessible and affordable therapeutic approaches to treat a broad spectrum of inflammatory and autoimmune diseases including type-1 diabetes, arthritis and multiple sclerosis.

Cryo-Save sponsors a multi-centre clinical trial investigating new treatments for cerebral palsy by infusing two types of stem cells derived from umbilical cord blood and tissue processed by Cryo-Save.

Cryo-Save together with the University of Cologne pioneered validated methods for cord tissue collection, viability testing, cryopreservation, and isolation of mesenchymal stem cells from umbilical cord tissue.

Cryo-Save is a founding member of the International Tissue Engineering Research Association, an international forum of scientists and researchers specialised in stem cells and tissue repair. Together with other universities in Europe and the Fruanhofer Institute, Cryo-Save has been selected to conduct fundamental research in the field of cryopreservation techniques for stem cells in an EU funded Framework Program.